BETH ISRAEL DEACONESS MEDICAL CENTER

Maxwell Lloyd, MD, discusses why elacestrant (Orserdu) shows better real-world outcomes than in the EMERALD trial, attributing it to less frequent restaging and diverse patient conditions. Real-world median progression-free survival (PFS) was 6.8 months vs. 3.8 months in the trial.

New data suggest AI, specifically metabolomics-based machine learning models, could revolutionize screening for metabolic dysfunction-associated steatohepatitis (MASH) candidates for resmetirom. Current noninvasive tests for noncirrhotic MASH with moderate-to-severe fibrosis have limitations, but machine learning models show potential to improve accuracy, sensitivity, and predictive ability. The study, led by Christos Mantzoros, assessed 28 biomarker-, imaging-, and algorithm-based noninvasive tests and developed machine learning models achieving higher AUC, sensitivity, and NPV. The addition of specific biomarkers to metabolomics-based models further enhanced performance.

NYU Langone Health recognized for contributions to patient safety and quality standards, pioneering cancer complication treatment with new microsurgery, and research on BRCA mutation carriers, gut-brain connections, epilepsy treatment, sleep disparities, breast cancer disparities, and humidifier benefits.

Novo Nordisk and Evotec select three projects for LAB eN², focusing on cardiometabolic diseases. LAB eN² expands to include Boston Children's Hospital, Johns Hopkins University, and others. The initiative leverages Evotec's R&D platform and Novo Nordisk's disease expertise for drug discovery.

The NEJM AI study shows Prenosis' Sepsis ImmunoScore™, an FDA-authorized AI diagnostic, accurately predicts sepsis and adverse outcomes, marking a shift from reactive to proactive sepsis care.

SageMedic Corp forms Business Advisory Board to complement its Scientific and Medical Advisory Board, aiming to expand functional precision oncology with the SAGE Oncotest™ platform. Board members include Archelle Georgiou, Scott Minick, Mika Newton, Michael Seiden, and Jeffrey Venstrom, each bringing unique expertise to guide SAGE's growth and strategic direction.

Danielle Griffin, despite easy access to weight loss drugs like Wegovy, found they didn't work for her, losing only 13 pounds in a year and a half. Experts estimate that up to 20% of patients may not respond well to these medications, influenced by factors like genetics, hormones, and medical conditions. Alternative drugs or lifestyle changes may be necessary for effective weight management.

A journalist tries a continuous glucose monitor (CGM) marketed as a wellness tool, finding it influences food choices and diet, unintentionally adopting a keto approach. Experts warn CGMs should be used correctly, as they are life-changing for insulin-dependent diabetics. Dexcom and Abbott now offer CGMs without prescriptions, aiming to provide health insights. The journalist's experience shows the CGM can affect eating habits and behavior, but scientific consensus on their value for non-diabetics is lacking.

HIV research transformed from a death sentence to a manageable condition, impacting COVID-19, cancer treatments, and vaccine development. Key insights include HIV's rapid mutation, integration into host DNA, and immune evasion, driving advancements in antiretroviral therapy and pre-exposure prophylaxis. Elite controllers' immune responses offer hope for a vaccine, with ongoing trials in Africa and South Africa.

Alzheimer’s disease research faces challenges due to complex pathology and model inaccuracies. A 3D cell culture model, 'Alzheimer’s in a dish,' and a computational tool, IPAA, identify 83 dysregulated pathways common to both human brains and the model, validating its use for drug testing and revealing potential targets like the p38 MAPK pathway.